Biotheranostics discovers and develops proprietary molecular-based tests that provide physicians with actionable information to help guide cancer treatment.
http://www.biotheranostics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.3 seconds
16x16
BIOMERIEUX
Servi●●●●●rques
MARCY●●●●●TOILE , FR, 69280
FR
View this contact
BIOMERIEUX
Servi●●●●●rques
MARCY●●●●●TOILE , Rhone Alpes, 69280
FR
View this contact
BUSINESS & DECISION INTERACTIVE EOLAS, SARL
29 r●●●●rvan
GRE●●●BLE , Rhone Alpes, 38000
FR
View this contact
BUSINESS & DECISION INTERACTIVE EOLAS, SARL
29 r●●●●rvan
GRE●●●BLE , Rhone Alpes, 38000
FR
View this contact
BUY YOUR DOMAIN
16
YEARS
10
MONTHS
27
DAYS
NAMEBAY
WHOIS : whois.namebay.com
REFERRED : http://www.namebay.com
PAGES IN
THIS WEBSITE
14
SSL
EXTERNAL LINKS
33
SITE IP
205.186.175.225
LOAD TIME
0.278 sec
SCORE
6.2
Biotheranostics | Molecular Diagnostics for Breast & Metastatic | biotheranostics.com Reviews
https://biotheranostics.com
Biotheranostics discovers and develops proprietary molecular-based tests that provide physicians with actionable information to help guide cancer treatment.
biotheranostics.com
Management Team | Biotheranostics
http://www.biotheranostics.com/about/management
Nicolas Barthelemy Chief Executive Officer. Sue Beruti Medical Director. Karla Kelly General Counsel. Matt Sargent Vice President of Sales. Catherine Schnabel Chief Scientific Officer. Jennifer Skeen Vice President of Clinical Operations. Gail A. Sloan Chief Financial Officer. Eric joined MVM in 2008. Before joining MVM, Eric was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, Eric was a Director in the Corporate Finance Group of Silic...Eric ...
Breast Cancer | Patient | Biotheranostics
http://www.biotheranostics.com/patients/bci
Know your risk of cancer recurrence and likelihood of benefit from anti-estrogen therapy beyond year 5. Recently, multiple clinical trials ( 20,000 women) have demonstrated that a small percentage (3-5%) of patients are likely to benefit if oral anti-estrogen medication is taken continuously for an additional five years (for a total of ten years). Breast Cancer Index (or BCI) is a new test to help determine if you. Are likely to benefit from an additional five years of anti-estrogen medication. BCI c...
Press Room | Biotheranostics
http://www.biotheranostics.com/press
Biotheranostics’ New bioT3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing with Integration of Next Generation Sequencing. February 3, 2014. Biotheranostics is Now the Industry Leading Provider of Genomic Solutions Across the Continuum of Metastatic Cancer Management. Biotheranostics Signs Collaboration Agreement with Top U.S. Hospital and Reference Laboratory to Offer CancerTYPE ID Molecular Test for Metastatic Cancer. October 29, 2013. Biotheranostics’ Breast Cancer Index. July 10, 20...
Publications | Biotheranostics
http://www.biotheranostics.com/healthcare-professionals/publications
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Breast Cancer Index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. A five-gene molecular gra...
Investors | Biotheranostics
http://www.biotheranostics.com/investors
Translating Science into Solutions for Individualized Patient Care. Biotheranostics is a commercial stage molecular diagnostics company focused on cancer. We have two high-value proprietary and uniquely differentiated tests on the market, focused on critical areas of unmet medical needs. We are entering a rapid-growth phase with increasingly diversified growth drivers. Biotheranostics has entered a rapid-growth phase with increasingly diversified growth drivers. Download Our Investor Presentation. Yale S...
TOTAL PAGES IN THIS WEBSITE
14
Prognostic Studies | Breast Cancer Index
http://www.breastcancerindex.com/prognostic-studies
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? BCI Prognostic Model Now Validated for LN patients (1-3 nodes). BCI Prognostic LN- Validations. Consistent stratification in two distinct risk categories:.
Predictive Studies | Breast Cancer Index
http://www.breastcancerindex.com/predictive-studies
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? The only validated test to help inform your decision to extend or end endocrine therapy. Patients with HIGH Breast Cancer Index (BCI). Cases from patients with ...
BCI Test Report | Breast Cancer Index
http://www.breastcancerindex.com/site-map
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? BreastCancerIndex.com Privacy Statement. Understanding the Unmet Need. Major Safety and Tolerability Challenges. Side Effects Lead to Noncompliance.
Major Safety and Tolerability Challenges | Breast Cancer Index
http://www.breastcancerindex.com/major-safety-and-tolerability-challenges
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? Major Safety and Tolerability Challenges. Extended 10-year treatment poses major safety and tolerability challenges. For every 600 women. Breast Cancer Index - ...
Ordering Breast Cancer Index (BCI) | Breast Cancer Index
http://www.breastcancerindex.com/ordering
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? Ordering Breast Cancer Index (BCI). Click here for detailed information about Medicare coverage (certain coverage limitations apply). Offered in all 50 states.
Patient Scenarios | Breast Cancer Index
http://www.breastcancerindex.com/patient-scenarios
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? The only validated test to help inform your decision to extend or end endocrine therapy. Select a patient to read a full case. Who are poorly compliant. Biother...
About The Test | Breast Cancer Index
http://www.breastcancerindex.com/about-breast-cancer-index
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? About Breast Cancer Index (BCI). In one test, BCI combines two complementary gene-expression signatures to assess proliferative and estrogen signaling pathways.
Modest Benefit From Extended Endocrine Therapy | Breast Cancer Index
http://www.breastcancerindex.com/modest-benefit-from-extended-endocrine-therapy
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? Modest Benefit From Extended Endocrine Therapy. According to clinical trials, most patients on extended endocrine therapy are not likely to benefit. With extend...
Presentations and Publications | Breast Cancer Index
http://www.breastcancerindex.com/presentations-and-publications
Understanding the Unmet Need. Major Safety and Tolerability Challenges. Modest Benefit From Extended Endocrine Therapy. Side Effects and Noncompliance. Traditional Factors and Genomic Tools do not Inform Treatment Beyond Year 5. About Breast Cancer Index (BCI). Adjuvant Systemic Therapy Decision Making. How Does BCI Help You Personalize Her Path? Published: December 7, 2015. Published: September 1, 2013. Published: August 1, 2013. Published: June 28, 2013. Health Economic Analysis of Breast Cancer Index ...
TOTAL LINKS TO THIS WEBSITE
33
Home
Nanoparticles, Quo Vadis? Laboratoire Matière et Systèmes Complexes (MSC) CNRS / Université Paris Diderot. 10 rue Alice Domon et Léonie Duquet. 75205 Paris Cedex 13 - France. 33) 01 57 27 62 03. 33) 01 57 27 62 11. Http:/ www.msc.univ-paris-diderot.fr.
Biothera
Publication & Research. News & Events. Unlocking the promise of cancer immunotherapy. An ignition switch to drive a coordinated immune response against cancer. Promising combination therapies with immune checkpoint inhibitors. Is underway for studies in melanoma, triple negative breast cancer, non-small cell lung cancer and head and neck cancer. Significant milestones, including response, safety and biomarker data, are expected through 2017-18. Biothera Pharmaceuticals was recently featured in. Biothera ...
Engineers Talents - Hot oil industry jobs - Engineers Talent
FIND YOUR FUTURE JOB. Search by job title. We've helped to select your country. HOT ENGINEERS TALENT JOBS. Es simplemente el texto de relleno de las imprentas y archivos. Es simplemente el texto de relleno de las imprentas y archivos. Quisquam quasi dolorem quia sed. Inventore consectetur quisquam ullam ad pariatur. Aperiam et commod. Doloremque praesentium voluptate praesentium aliquid. Quisquam doloribus minus maiores voluptatibus. Able Bodied Watchman (AB Watchman). Aut ut incidunt odio quae voluptate...
This site is under development
This site is under development. This page indicates the webmaster has not uploaded a website to the server. For information on how to build or upload a site, please visit your web hosting company's site.
Biotheranostics | Molecular Diagnostics for Breast & Metastatic
Translating science into solutions for individualized patient care. Biotheranostics discovers, develops, and commercializes proprietary molecular-based diagnostic, prognostic, and predictive tests that provide physicians with actionable information to help guide cancer treatment. Bringing the abstract to the here and now. Extensive research generates high-complexity molecular tools that help physicians execute more informed treatment decisions in clinical practice every day.
Biotherapeudix Home
biotherapeute.com
Equipo y productos Bio-Therapeutic para el cuidado de la piel establecido el 1974 en Seattle WA EE.UU.
Cuidado de la piel Bio-Therapeutic. Cual es su acento? Bt-accent™ LED la adicion perfecta. Lampara de aumento portatil. Tecnologia de LED de luz blanca brillante y de UV. Elegido como el equipo #1. Eso es muy cierto. Sistema estrategico de energia de tres partes para la piel. Conocimiento del producto de acuerdo con el tipo y la condicion de la piel. Descubrimiento de Bio-Therapeutic: tecnologias portatiles, de respaldo y lideres. Exposicion itinerante Bio-Therapeutic en Londres. David Suzuki, presidente:.
biotherapeutic.mobi - Crazy Domains
Search and register domain names. Move your domains to us FREE. Everything you need for your domains. Express cheap domain renewal. Control your CNAME, MX and A records. 700 New global domains. Get the domain name you want. Find who owns a particular domain. Earn points with every purchase. Sell domains under your brand. Get paid commission on referrals. Register your domain and Get Started Online. Fast, reliable space for your website. Web Hosting - Transfer. Move your website and email to us. Activate ...
The domain www.biotherapeuticcolonizer.com is registered by NetNames
The domain name www.biotherapeuticcolonizer.com. Has been registered by NetNames. Every domain name comes with free web and email forwarding. To forward your domain name to another web page or site, log into your control panel at www.netnames.com. And change the web forwarding settings.
